32 related articles for article (PubMed ID: 11868972)
1. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation.
Xiao Z; Cui X; Liu F; Wang Y; Liu X; Zhou W; Zhang Y
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167149. PubMed ID: 38565383
[TBL] [Abstract][Full Text] [Related]
2. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.
Temizoz B; Shibahara T; Hioki K; Hayashi T; Kobiyama K; Lee MSJ; Surucu N; Sag E; Kumanogoh A; Yamamoto M; Gursel M; Ozen S; Kuroda E; Coban C; Ishii KJ
Front Immunol; 2024; 15():1353336. PubMed ID: 38533502
[TBL] [Abstract][Full Text] [Related]
3. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
[TBL] [Abstract][Full Text] [Related]
4. Transport of thalidomide by the human intestinal caco-2 monolayers.
Zhou S; Li Y; Kestell P; Schafer P; Chan E; Paxton JW
Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):49-61. PubMed ID: 16010862
[TBL] [Abstract][Full Text] [Related]
5. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Zhou S; Kestell P; Paxton JW
Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
[TBL] [Abstract][Full Text] [Related]
6. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Zhou S; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
[TBL] [Abstract][Full Text] [Related]
9. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
[TBL] [Abstract][Full Text] [Related]
10. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Zhou SF; Tingle MD; Kestell P; Paxton JW
Xenobiotica; 2002 Feb; 32(2):87-107. PubMed ID: 11868972
[TBL] [Abstract][Full Text] [Related]
11. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
